Premium
PATIENT‐REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY
Author(s) -
Prince H.M.,
Dummer R.,
Whittaker S.,
Horwitz S.,
Duvic M.,
Scarisbrick J.,
Quaglino P.,
Zinzani P.L.,
Wolter P.,
Sanches J.,
OrtizRomero P.,
Akilov O.,
Geskin L.,
Huen A.,
Wang Y.,
PalancaWessels M.C.,
Richhariya A.,
Feliciano J.,
Zhu Y.,
Lin H.,
Liu Y.,
Little M.,
Zagadailov E.,
Dalal M.,
Kim Y.H.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_110
Subject(s) - brentuximab vedotin , mycosis fungoides , medicine , clinical endpoint , cutaneous t cell lymphoma , quality of life (healthcare) , population , bexarotene , cd30 , surrogate endpoint , lymphoma , oncology , randomized controlled trial , biochemistry , chemistry , nursing , environmental health , nuclear receptor , transcription factor , gene